C16
C16
C16
| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-1329-5MG | C16 | 5mg | $158.00 | |
| GBM-1329-25MG | C16 | 25mg | $609.00 |
| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-1329-5MG | C16 | 5mg | $158.00 | |
| GBM-1329-25MG | C16 | 25mg | $609.00 |
| Bioassays Specification | |
| Bio-Activity | PKR kinase inhibitor |
| Chemical Name | 6,8-Dihydro-8-(1H-imidazol-5-ylmethylene)-7H-pyrrolo[2,3-g]benzothiazol-7-one |
| Function / Pharmacology | Inhibits RNA-dependent protein kinase (PKR, IC50 = 210 nM)1. Inhibits ER stress-induced neuronal damage2. Reduces brain PKR activation in vivo3. Prevents apoptosis and IL-1β production in an acute excitotoxic and neuroinflammatory rat model4. Prevents β-amyloid peptide-induced inflammation in primary murine mixed co-cultures5. Cell permeable. |
| CAS# | 608512-97-6 |
| MW | 268.30 |
| Molecular Formula | C13H8N4OS |
| Solubility | Soluble in DMSO (up to 15 mg/ml, with warming). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Jammi et al. (2003), Small molecule inhibitors of the RNA-dependent protein kinase; Biochem. Biophys. Res. Commun., 308 50 2) Shimazawa et al. (2007), Involvement of double-stranded RNA-dependent protein kinase in ER stress-induced retinal neuron damage; Ophthalmol. Vis. Sci., 48 3729 3) Ingrand et al. (2007), The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation; FEBS Lett. 581 4473 4) Tronel et al. (2014), The specific PKR inhibitor C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component; Neurochem. Int. 64 73 5) Couturier et al. (2011) Prevention of the β-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures; Neuroinflammation, 8 72 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | PKR kinase inhibitor |
| Chemical Name | 6,8-Dihydro-8-(1H-imidazol-5-ylmethylene)-7H-pyrrolo[2,3-g]benzothiazol-7-one |
| Function / Pharmacology | Inhibits RNA-dependent protein kinase (PKR, IC50 = 210 nM)1. Inhibits ER stress-induced neuronal damage2. Reduces brain PKR activation in vivo3. Prevents apoptosis and IL-1β production in an acute excitotoxic and neuroinflammatory rat model4. Prevents β-amyloid peptide-induced inflammation in primary murine mixed co-cultures5. Cell permeable. |
| CAS# | 608512-97-6 |
| MW | 268.30 |
| Molecular Formula | C13H8N4OS |
| Solubility | Soluble in DMSO (up to 15 mg/ml, with warming). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Jammi et al. (2003), Small molecule inhibitors of the RNA-dependent protein kinase; Biochem. Biophys. Res. Commun., 308 50 2) Shimazawa et al. (2007), Involvement of double-stranded RNA-dependent protein kinase in ER stress-induced retinal neuron damage; Ophthalmol. Vis. Sci., 48 3729 3) Ingrand et al. (2007), The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation; FEBS Lett. 581 4473 4) Tronel et al. (2014), The specific PKR inhibitor C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component; Neurochem. Int. 64 73 5) Couturier et al. (2011) Prevention of the β-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures; Neuroinflammation, 8 72 |
| Protein Specification | |
| Purity | >98% |